Claim Missing Document
Check
Articles

Found 6 Documents
Search

Retroperitoneum parasitic leiomyoma: Dilemmatic diagnostic Setyo Teguh Waluyo; Hariadi Yuseran; Ferry Armanza; Yuvens Richardo Wibowo
Majalah Obstetri dan Ginekologi Vol. 29 No. 2 (2021): August
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/mog.V29I22021.72-75

Abstract

HIGHLIGHTS1. Parasitic leimyoma was found in a 38 year-old woman with complaint of mass in lower abdomen and already done biopsy by laparotomy 4 months before.2. During operation, the tumor was detached from the uterus, located retroperitoneally as high as L4 – S1 vertebrae.3. The tumor had been confirmed intraoperatively and proven histopathologically as parasitic leimyoma.4. Retroperitoneal parasitic leiomyoma is of a rare type and it needs multidisciplinary examination and approaches to increase the quality of its management.ABSTRACTObjectives: To describe a retroperitoneum parasitic leiomyoma case: a dilemma in diagnosis and operation finding.Case Report: A 38 year-old woman with 3 children visited Ulin Hospital, Banjarmasin, Indonesia, with complaint of mass in lower abdomen and about 4 months before, she underwent biopsy by laparotomy which revealed leiomyoma. Parasitic leiomyoma is a rare type of leiomyoma with predilection area in broad ligament, pelvic peritoneum, pouch of douglas, and omentum. During operation, the tumor was detached from the uterus and located retroperitoneally as high as L4–S1. It had been confirmed intraoperatively and proven histopathologically as a leiomyoma.Conclusion: Retroperitoneal parasitic leiomyoma may cause a dilemma in the diagnosis. Multidiscipline examination and approaches may increase the quality of management. 
Gambaran Jumlah Leukosit pada Pasien Kanker Serviks yang Menerima Kemoterapi Jessica Manoralisa; Hariadi Hariadi; FX Hendriyono
Homeostasis Vol 3, No 1 (2020)
Publisher : Homeostasis

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (301.146 KB)

Abstract

Abstract: Cervical cancer is malignancy disease in cervix. Chemotherapy is cancer’s treatment using systemic drugs. This study determines the description of leukocytes number in cervical cancer patients who receive paclitaxel and carboplatin chemotherapy phases I, II, III and IV at Ulin General Hospital Banjarmasin in August 2018 - March 2019. This is descriptive study with cohort approach. The results showed 46 patients who appropriate the criteria, 1 patient with IB stage and 45 patients with IIIB stage. Patients with early-stage have normal leukocyte number before chemotherapy and after first, second and third chemotherapy then decrease after fourth chemotherapy. At advanced stage, leukocyte number have 12 patients (26.7%) increase before chemotherapy. Four patients (8.9%) increase and 5 patients (11.1%) decrease after first chemotherapy. One patient (2.2%)  increase and 7 patients (15.6%) decrease after second chemotherapy. One patient (2.2 increase after third chemotherapy and 11 patients (24.5%) decrease after third and fourth chemotherapy. Keywords: leukocyte, paclitaxel, carboplatin, cervical cancer. Abstrak: Kanker serviks adalah penyakit keganasan leher rahim. Kemoterapi adalah salah satu pengobatan dengan menggunakan obat sistemik. Penelitian ini dilakukan untuk mengetahui gambaran jumlah leukosit pasien kanker serviks yang menerima kemoterapi paklitaksel dan karboplatin fase I, II, III dan IV di RSUD Ulin Banjarmasin periode Agustus 2018 – Maret 2019. Penelitian bersifat deskriptif dengan desain kohort. Hasil penelitian didapatkan 46 pasien memenuhi kriteria, 1 pasien stadium IB dan 45 pasien stadium IIIB. Pada stadium awal didapatkan jumlah leukosit pasien normal sebelum kemoterapi dan sesudah kemoterapi pertama, kedua, ketiga kemudian menurun sesudah kemoterapi keempat. Pada pasien stadium lanjut didapatkan data jumlah leukosit sebanyak 12 pasien (26,7%) meningkat sebelum kemoterapi. Sebanyak 4 pasien (8,9%) meningkat dan 5 pasien (11,1%) menurun sesudah kemoterapi pertama. Sebanyak 1 pasien (2,2%) meningkat dan 7 pasien (15,6%) menurun sesudah kemoterapi kedua. Sebanyak 1 pasien (2,2%) meningkat sesudah kemoterapi ketiga dan 11 pasien (24,5%) menurun sesudah kemoterapi ketiga dan keempat. Kata-kata kunci: leukosit, paklitaksel, karboplatin, kanker serviks.
Gambaran Jumlah Trombosit pada Pasien Kanker Serviks yang Menerima Kemoterapi Rifdah Amalina Winarno; Hariadi Hariadi; FX Hendriyono
Homeostasis Vol 3, No 3 (2020)
Publisher : Homeostasis

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (215.926 KB)

Abstract

Abstract: Cervical cancer is a malignancy in the cervix. Chemotherapy is a therapy to kills cancer cells. The side effect of chemotherapy is myelosuppression which results in decreased platelet production. The purpose of study is to determine the description of platelets amount in cervical cancer patients who received paclitaxel and carboplatin chemotherapy phase I, II, III and IV at RSUD Ulin Banjarmasin. This study is descriptive by taking medical records data of cervical cancer patients at RSUD Ulin Banjarmasin period August 2018 - March 2019. The study obtained by 46 patients with cervical cancer included in the criteria. There are 1 patient (2,2%) stage IB and 45 patients (97,8%) stage IIIB. Platelet amount are 100% normal in phase I, II, III and IV stage IB cervical cancer patients. In stage IIIB, 14 patients (31,1%) increased and no decreased before chemotherapy. One patient (2,2%) decreased and nine patients (20%) increased after the first chemotherapy. Three patients (6,7%) decreased and four patients (8.9%) increased after the second chemotherapy. Five patients (11,1%) decreased and three patients (6,7%) increased after the third chemotherapy. Seven patients (15,6%) decreased and five patients (11,1%) increased after the fourth chemotherapy. Keywords: cervical cancer, platelet amount, chemotherapy Abstrak: Kanker serviks yaitu keganasan di leher rahim. Kemoterapi adalah terapi untuk menghancurkan sel kanker. Efek samping kemoterapi yaitu mielosupresi yang mengakibatkan terjadinya penurunan produksi trombosit. Tujuan penelitian ini untuk mengetahui gambaran jumlah trombosit pada pasien kanker serviks yang menerima kemoterapi paklitaksel dan karboplatin fase I, II, III dan IV di RSUD Ulin Banjarmasin. Penelitian ini bersifat deskriptif dengan pengambilan data rekam medik pasien kanker serviks di RSUD Ulin Banjarmasin periode Agustus 2018 – Maret 2019. Hasil penelitian diperoleh 46 pasien kanker serviks yang memenuhi kriteria. Terdapat 1 pasien (2,2%) stadium IB dan 45 pasien (97,8%) stadium IIIB. Jumlah trombosit 100 % normal pada pasien kanker serviks stadium IB fase I, II, III dan IV. Pada stadium IIIB, didapatkan 14 pasien (31,1%) meningkat dan tidak ada yang menurun sebelum kemoterapi. Sebanyak 1 pasien (2,2%) menurun dan 9 pasien (20%) meningkat sesudah kemoterapi pertama. Sebanyak 3 pasien (6,7%) menurun dan 4 pasien (8,9%) meningkat sesudah kemoterapi kedua. Sebanyak 5 pasien (11,1%) menurun dan 3 pasien (6,7%) meningkat sesudah kemoterapi ketiga. Sebanyak 7 pasien (15,6%) menurun dan 5 pasien (11,1%) meningkat sesudah kemoterapi keempat. Kata-kata kunci:  Kanker serviks, jumlah trombosit, kemoterapi
Gambaran Kadar Kreatinin Darah pada Pasien Kanker Serviks yang Menerima Kemoterapi Aghfierna Herza Berliana; Hariadi Hariadi; FX Hendriyono
Homeostasis Vol 3, No 2 (2020)
Publisher : Homeostasis

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (221.426 KB)

Abstract

Abstract: One of the treatment modality for cervical cancer is chemotherapy. Paclitaxel and carboplatin are chemotherapy regiment that being used in Ulin General Hospital Banjarmasin. The aimed of this study is to know the overview of blood creatinine level in cervical cancer patient receiving paclitaxel and carboplatin chemotherapy phase I, II, III and IV. The study was descriptive study with cohort design study. Results obtained 42 patient that fulfill criteria. In IB stage the blood creatinine level are still at normal range either when before chemotherapy or after chemotherapy phase I, II, III and IV. In IIIB stage was obtained 1 patient (2,44%) experienced a decrease of blood creatinine level before chemotherapy. After first chemotherapy 1 patient (2,44%) experienced an increase. After second chemotherapy 1 patient (2,44%) experienced an increase and 1 patient (2,44%) experienced a decrease. After third and fourth chemotherapy 3 patient (4,88%) experienced an increase. Keywords: creatinine blood level , carboplatin, paclitaxel, cervical cancer Abstrak: Salah satu modalitas pengobatan kanker serviks adalah kemoterapi. Paklitaksel dan karboplatin merupakan salah satu regimen kemoterapi yang digunakan di RSUD Ulin Banjarmasin. Penelitian ini bertujuan untuk mengetahui gambaran kadar kreatinin darah pada pasien kanker serviks yang menerima kemoterapi paklitaksel dan karboplatin pada fase I, II, III dan IV. Penelitian ini bersifat deskritif dengan menggunakan desain studi kohort. Hasil penelitian diperoleh 42 pasien yang memenuhi kriteria. Pada stadium IB kadar kreatinin masih dalam batas normal baik pada pengukuran sebelum kemoterapi yang pertama maupun sesudah kemoterapi fase I, II, III dan IV. Pada stadium IIIB didapatkan sebanyak 1 pasien (2,44%) mengalami penurunan kadar kreatinin sebelum kemoterapi. Sebanyak 1 pasien (2,44%) mengalami peningkatan sesudah kemoterapi yang pertama. Sebanyak 1 pasien (2,44%) mengalami peningkatan dan 1 pasien (2,44%) mengalami penurunan sesudah kemoterapi yang kedua. Sebanyak 2 pasien (4,88%) mengalami peningkatan yang sesudah kemoterapi yang ketiga dan keempat. Kata-kata kunci:  kadar kreatinin darah, karboplatin, paklitaksel, kanker serviks
GAMBARAN TATALAKSANA PASIEN PREEKLAMPSIA YANG TERKONFIRMASI COVID-19 DAN NON-COVID-19 DI RSUD ULIN BANJARMASIN Nor Hayatun Thaibah; Ferry Armanza; Siti Wasilah; Hariadi Yuseran; Lena Rosida
Homeostasis Vol 5, No 3 (2022)
Publisher : Homeostasis

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Preeclampsia is hypertension in pregnancy which is characterized with blood pressure of 140/90 mmHg after 20 weeks of gestation, accompanied by proteinuria.3. There are three types of drugs that are often used in preeclampsia treatment, they are nifedipine, methyldopa, and MgSO4. This study was aimed to find out the description of confirmed covid-19 and non covid-19 preeclampsia patients treatment at Ulin Hospital, Banjarmasin in the COVID-19 period seen from administration of MgSO4, antihypertensive, method and time of termination. This study applied descriptive method with data collection through medical records. The sampling technique used purposive sampling which was selected based on the criteria. In this study, a sample of 176 preeclampsia patients with confirmed COVID-19 and non-COVID-19 were  obtained. However, from the 176 samples, which met the criteria, only 55 preeclampsia patients had confirmed COVID-19 and 80 non-COVID-19 preeclampsia patients. The results showed that all severe preeclampsia patients with confirmed COVID-19 were given MgSO4 with a percentage of 100%.. Antihypertensives were often given was a combination of methyldopa + nifedipine. The most common method of delivery was by cesarean section.
Characteristics of outpatient gynecology oncology services before and after COVID-19 pandemic at Ulin Regional General Hospital, Banjarmasin, Indonesia Setyo Teguh Waluyo; Ferry Armanza; Hariadi Yuseran; Kevin Stanley Halim
Majalah Obstetri & Ginekologi Vol. 31 No. 2 (2023): August
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/mog.V31I22023.68-74

Abstract

HIGHLIGHTS The characteristics of gynecology oncology services at Ulin Regional General Hospital before and after the COVID-19 pandemic were evaluated. There was a decrease of 19% in the number of visits by Gynecology Oncology Clinic patients at Ulin Regional General Hospital between the period of March 2019 - February 2020 and March 2020 - February 2021.   ABSTRACT Objective: The aim of this study was to investigate the characteristics of the Gynecology Oncology Outpatient Clinic at Ulin Hospital Banjarmasin before and after the COVID-19 pandemic. Materials and Methods: This descriptive study utilized existing patient data from the Gynecology Oncology Outpatient Clinic at Ulin Hospital Banjarmasin covering the period from March 2019 to February 2021. The study received ethical approval from the Ulin General Hospital ethics committee with clearance number 10/I-Reg Research/RSUDU/23. The collected data was presented in a tabular format to compare the service characteristics before the pandemic (March 2019 - February 2020) and after the pandemic (March 2020 – February 2021). Results: During the periods of March 2019 – February 2020 and March 2020 – February 2021, there was a reduction of 19% in patient visits. The number of patients undergoing treatment also decreased, from 1081 patients (53.9%) in the period of March 2019 – February 2020 to 926 patients (46.1%) in the period of March 2020 – February 2021. Notably, there was a decrease in the number of patients undergoing surgical procedures, dropping from 76 patients (70.4%) in the period of March 2019 – February 2020 to 32 patients (29.6%) in the period of March 2020 – February 2021. A similar trend was seen in patients receiving chemotherapy, with the count decreasing from 1005 patients (52.9%) in the period of March 2019 – February 2020 to 894 patients (47.1%) in the period of March 2020 – February 2021. These changes were attributed to various hospital measures implemented to address the COVID-19 pandemic, including a reduction in outpatient clinic visits and the temporary suspension of surgical procedures from March 2020 to October 2020 to minimize potential exposure. Conclusion: The study highlights a noticeable decline in both the frequency of visits to the Gynecology Oncology Outpatient Clinic at Ulin Regional General Hospital Banjarmasin and the number of patients receiving treatment during the periods before and after the onset of the COVID-19 pandemic.